Donald Suh, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $857 and has fallen 86.3% since, to $118 in 2025. That places this record below the midpoint for urology clinicians in DE, where the typical reported total is $2,396.
Across 105 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$366
- Astellas Pharma US Inc$351
- Boston Scientific$159
- Pfizer$142
- Johnson & Johnson$135
- Neotract Inc.$125
- plus $822 from 25 others
What the payments were for
- Food & beverage$2,08599%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $366 |
| Astellas Pharma US Inc | 18 | $351 |
| Boston Scientific | 7 | $159 |
| Pfizer | 10 | $142 |
| Johnson & Johnson | 8 | $135 |
| Neotract Inc. | 2 | $125 |
| Teleflex LLC | 5 | $100 |
| Coloplast | 2 | $64 |
| Amgen | 3 | $56 |
| Endo Pharmaceuticals Inc. | 4 | $56 |
| Urogen Pharma, Inc. | 2 | $50 |
| Baxter Healthcare | 2 | $41 |
| Urovant Sciences Inc | 2 | $38 |
| Bioprotect Medical, Inc. | 2 | $37 |
| Verity Pharmaceuticals Inc. | 2 | $37 |
| Ferring Pharmaceuticals Inc. | 1 | $36 |
| Myovant Sciences Inc. | 2 | $30 |
| Acerus Pharmaceuticals Corporation | 2 | $29 |
| Tolmar, Inc. | 1 | $28 |
| Axonics, Inc. | 1 | $27 |
| Dendreon Pharmaceuticals LLC | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Novartis | 1 | $18 |
| Abbott | 1 | $18 |
| Olympus America Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $13 |
| AstraZeneca | 1 | $13 |
| Blue Earth Diagnostics | 1 | $13 |
| Laborie Medical Technologies Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$107
How this compares
$2,099 in reported general payments places this provider in the 40th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 74 | $67,516 |
| Tamsulosin Hcl | 1,034 | $17,760 |
| Finasteride | 449 | $8,501 |
| GemtesaVibegron | 13 | $5,938 |
| Trospium Chloride ErTrospium Chloride | 16 | $2,470 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 98 | $1,411 |
| Solifenacin Succinate | 21 | $1,347 |
| Testosterone | 13 | $1,331 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 31 | $1,122 |
| Dutasteride | 24 | $891 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 127 | $856 |
| Cefdinir | 35 | $465 |
| Ciprofloxacin Hcl | 50 | $311 |
| Levofloxacin | 91 | $253 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 51 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $351 | $67,51674 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $5,93813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 33 urology providers in Delaware.
Other urology in Dover
- Joohyong KimDover$7K
- Christopher VallorosiDover$7K
- Michael ZaragozaDover$6K
- Gregory SpanaDover$5K
- Raj KurpadDover$3K
- Jason WaltherDover$87
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Thomas DesperitoWilmington$7K
- Raymond BolognaMilford$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.